Related Experiment Videos
Combined androgen blockade: an update
1Division of Urology, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ontario M4N 3M5, Canada. Laurence.klotz@sw.ca
The Urologic Clinics of North America
|April 25, 2006
Summary
Combined androgen blockade therapy using bicalutamide may improve survival in prostate cancer patients compared to castration alone. However, potential side effects must be weighed against survival benefits for quality of life.
Area of Science:
- Oncology
- Pharmacology
Background:
- Combined androgen blockade (CAB) therapy for prostate cancer is controversial.
- Non-steroidal anti-androgens (NSAAs) aim to block androgen receptor activation in an androgen-depleted environment.
Purpose of the Study:
- To review the efficacy of NSAAs, specifically comparing bicalutamide to first-generation anti-androgens (flutamide, nilutamide).
- To evaluate the potential survival benefit of bicalutamide in combination therapy for prostate cancer.
Main Methods:
- Literature review of non-steroidal anti-androgens and their role in prostate cancer treatment.
- Comparative analysis of bicalutamide versus first-generation anti-androgens.
- Estimation of survival advantage for combined therapy.
Main Results:
- Bicalutamide demonstrates potential in blocking androgen receptor activation.
- Combined therapy with bicalutamide 50 mg shows a high probability of survival advantage over castration alone.
- Increased side effects and potential negative impact on quality of life are associated with this treatment.
Conclusions:
- Combined therapy with bicalutamide 50 mg may offer a survival benefit in prostate cancer management.
- Treatment decisions require balancing survival gains against potential adverse effects on patient quality of life.